ID   HDAC6_HUMAN             Reviewed;        1215 AA.
AC   Q9UBN7; O94975; Q6NT75; Q7L3E5; Q96CY0;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   18-JUN-2025, entry version 226.
DE   RecName: Full=Protein deacetylase HDAC6 {ECO:0000305};
DE            EC=3.5.1.- {ECO:0000269|PubMed:26080397, ECO:0000269|PubMed:30538141, ECO:0000269|PubMed:30770470, ECO:0000269|PubMed:31857589};
DE   AltName: Full=E3 ubiquitin-protein ligase HDAC6 {ECO:0000305};
DE            EC=2.3.2.- {ECO:0000269|PubMed:24882211};
DE   AltName: Full=Tubulin-lysine deacetylase HDAC6 {ECO:0000305};
DE            EC=3.5.1.- {ECO:0000269|PubMed:12024216, ECO:0000269|PubMed:20308065};
GN   Name=HDAC6 {ECO:0000303|PubMed:10220385, ECO:0000312|HGNC:HGNC:14064};
GN   Synonyms=KIAA0901 {ECO:0000303|PubMed:10048485}; ORFNames=JM21;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ILE-994.
RX   PubMed=10220385; DOI=10.1073/pnas.96.9.4868;
RA   Grozinger C.M., Hassig C.A., Schreiber S.L.;
RT   "Three proteins define a class of human histone deacetylases related to
RT   yeast Hda1p.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:4868-4873(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10048485; DOI=10.1093/dnares/5.6.355;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 5:355-364(1998).
RN   [3]
RP   SEQUENCE REVISION.
RA   Ohara O., Suyama M., Kikuno R., Nagase T., Ishikawa K.;
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ILE-994.
RC   TISSUE=Brain;
RA   Strom T.M., Gutwillinger N., Nyakatura G., Hellebrand H., Drescher B.,
RA   Rosenthal A., Meindl A.;
RT   "Transcription map in Xp11.23.";
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ASP-1200.
RC   TISSUE=Ovary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=11533236; DOI=10.1128/mcb.21.19.6470-6483.2001;
RA   Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N.,
RA   Downing J.R., Meyers S., Hiebert S.W.;
RT   "ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with
RT   multiple histone deacetylases and binds mSin3A through its oligomerization
RT   domain.";
RL   Mol. Cell. Biol. 21:6470-6483(2001).
RN   [9]
RP   INTERACTION WITH HDAC11.
RX   PubMed=11948178; DOI=10.1074/jbc.m111871200;
RA   Gao L., Cueto M.A., Asselbergs F., Atadja P.;
RT   "Cloning and functional characterization of HDAC11, a novel member of the
RT   human histone deacetylase family.";
RL   J. Biol. Chem. 277:25748-25755(2002).
RN   [10]
RP   SUMOYLATION.
RX   PubMed=12032081; DOI=10.1093/emboj/21.11.2682;
RA   Kirsh O., Seeler J.-S., Pichler A., Gast A., Mueller S., Miska E.,
RA   Mathieu M., Harel-Bellan A., Kouzarides T., Melchior F., Dejean A.;
RT   "The SUMO E3 ligase RanBP2 promotes modification of the HDAC4
RT   deacetylase.";
RL   EMBO J. 21:2682-2691(2002).
RN   [11]
RP   UBIQUITINATION, ACTIVE SITE, AND MUTAGENESIS OF HIS-216 AND HIS-611.
RX   PubMed=12354939; DOI=10.1073/pnas.172511699;
RA   Hook S.S., Orian A., Cowley S.M., Eisenman R.N.;
RT   "Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ
RT   domain) and copurifies with deubiquitinating enzymes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:13425-13430(2002).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=12024216; DOI=10.1038/417455a;
RA   Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A.,
RA   Yoshida M., Wang X.-F., Yao T.-P.;
RT   "HDAC6 is a microtubule-associated deacetylase.";
RL   Nature 417:455-458(2002).
RN   [13]
RP   INTERACTION WITH SIRT2.
RX   PubMed=12620231; DOI=10.1016/s1097-2765(03)00038-8;
RA   North B.J., Marshall B.L., Borra M.T., Denu J.M., Verdin E.;
RT   "The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin
RT   deacetylase.";
RL   Mol. Cell 11:437-444(2003).
RN   [14]
RP   FUNCTION, INTERACTION WITH AURKA, SUBCELLULAR LOCATION, AND PHOSPHORYLATION
RP   BY AURKA.
RX   PubMed=17604723; DOI=10.1016/j.cell.2007.04.035;
RA   Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A.;
RT   "HEF1-dependent Aurora A activation induces disassembly of the primary
RT   cilium.";
RL   Cell 129:1351-1363(2007).
RN   [15]
RP   INTERACTION WITH DDIT3.
RX   PubMed=17872950; DOI=10.1074/jbc.m703735200;
RA   Ohoka N., Hattori T., Kitagawa M., Onozaki K., Hayashi H.;
RT   "Critical and functional regulation of CHOP (C/EBP homologous protein)
RT   through the N-terminal portion.";
RL   J. Biol. Chem. 282:35687-35694(2007).
RN   [16]
RP   FUNCTION.
RX   PubMed=17846173; DOI=10.1083/jcb.200611128;
RA   Olzmann J.A., Li L., Chudaev M.V., Chen J., Perez F.A., Palmiter R.D.,
RA   Chin L.S.;
RT   "Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to
RT   aggresomes via binding to HDAC6.";
RL   J. Cell Biol. 178:1025-1038(2007).
RN   [17]
RP   INTERACTION WITH SIRT2.
RX   PubMed=17516032; DOI=10.1007/s11010-007-9478-6;
RA   Nahhas F., Dryden S.C., Abrams J., Tainsky M.A.;
RT   "Mutations in SIRT2 deacetylase which regulate enzymatic activity but not
RT   its interaction with HDAC6 and tubulin.";
RL   Mol. Cell. Biochem. 303:221-230(2007).
RN   [18]
RP   INTERACTION WITH BBIP1.
RX   PubMed=19081074; DOI=10.1016/j.devcel.2008.11.001;
RA   Loktev A.V., Zhang Q., Beck J.S., Searby C.C., Scheetz T.E., Bazan F.,
RA   Slusarski D.C., Sheffield V.C., Jackson P.K., Nachury M.V.;
RT   "A BBSome subunit links ciliogenesis, microtubule stability and
RT   acetylation.";
RL   Dev. Cell 15:854-865(2008).
RN   [19]
RP   INTERACTION WITH UBD.
RX   PubMed=19033385; DOI=10.1242/jcs.035006;
RA   Kalveram B., Schmidtke G., Groettrup M.;
RT   "The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to
RT   aggresomes under proteasome inhibition.";
RL   J. Cell Sci. 121:4079-4088(2008).
RN   [20]
RP   FUNCTION.
RX   PubMed=18606987; DOI=10.1073/pnas.0803749105;
RA   Parmigiani R.B., Xu W.S., Venta-Perez G., Erdjument-Bromage H., Yaneva M.,
RA   Tempst P., Marks P.A.;
RT   "HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox
RT   regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:9633-9638(2008).
RN   [21]
RP   ALTERNATIVE SPLICING (ISOFORM 2).
RX   PubMed=20102703; DOI=10.1016/j.bbrc.2010.01.091;
RA   Zhuang Y., Nguyen H.T., Lasky J.A., Cao S., Li C., Hu J., Guo X.,
RA   Burow M.E., Shan B.;
RT   "Requirement of a novel splicing variant of human histone deacetylase 6 for
RT   TGF-beta1-mediated gene activation.";
RL   Biochem. Biophys. Res. Commun. 392:608-613(2010).
RN   [22]
RP   INTERACTION WITH CYLD.
RX   PubMed=19893491; DOI=10.1038/emboj.2009.317;
RA   Wickstrom S.A., Masoumi K.C., Khochbin S., Fassler R., Massoumi R.;
RT   "CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and
RT   increasing the levels of acetylated tubulin.";
RL   EMBO J. 29:131-144(2010).
RN   [23]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH TPPP.
RX   PubMed=20308065; DOI=10.1074/jbc.m109.096578;
RA   Tokesi N., Lehotzky A., Horvath I., Szabo B., Olah J., Lau P., Ovadi J.;
RT   "TPPP/p25 promotes tubulin acetylation by inhibiting histone deacetylase
RT   6.";
RL   J. Biol. Chem. 285:17896-17906(2010).
RN   [24]
RP   INTERACTION WITH TPPP.
RX   PubMed=23093407; DOI=10.1074/jbc.m112.394965;
RA   Schofield A.V., Steel R., Bernard O.;
RT   "Rho-associated coiled-coil kinase (ROCK) protein controls microtubule
RT   dynamics in a novel signaling pathway that regulates cell migration.";
RL   J. Biol. Chem. 287:43620-43629(2012).
RN   [25]
RP   INVOLVEMENT IN CDP-PBHM.
RX   PubMed=20181727; DOI=10.1093/hmg/ddq083;
RA   Simon D., Laloo B., Barillot M., Barnetche T., Blanchard C., Rooryck C.,
RA   Marche M., Burgelin I., Coupry I., Chassaing N., Gilbert-Dussardier B.,
RA   Lacombe D., Grosset C., Arveiler B.;
RT   "A mutation in the 3'-UTR of the HDAC6 gene abolishing the post-
RT   transcriptional regulation mediated by hsa-miR-433 is linked to a new form
RT   of dominant X-linked chondrodysplasia.";
RL   Hum. Mol. Genet. 19:2015-2027(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   FUNCTION.
RX   PubMed=24413532; DOI=10.1158/0008-5472.can-13-2020;
RA   Kang H.J., Lee M.H., Kang H.L., Kim S.H., Ahn J.R., Na H., Na T.Y.,
RA   Kim Y.N., Seong J.K., Lee M.O.;
RT   "Differential regulation of estrogen receptor alpha expression in breast
RT   cancer cells by metastasis-associated protein 1.";
RL   Cancer Res. 74:1484-1494(2014).
RN   [29]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH DYSF AND RIPOR2.
RX   PubMed=24687993; DOI=10.1096/fj.13-246470;
RA   Balasubramanian A., Kawahara G., Gupta V.A., Rozkalne A., Beauvais A.,
RA   Kunkel L.M., Gussoni E.;
RT   "Fam65b is important for formation of the HDAC6-dysferlin protein complex
RT   during myogenic cell differentiation.";
RL   FASEB J. 28:2955-2969(2014).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1016; THR-1021; THR-1027;
RP   THR-1031; THR-1034; SER-1035 AND THR-1040, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=24882211; DOI=10.1016/j.molcel.2014.04.028;
RA   Zhang M., Xiang S., Joo H.Y., Wang L., Williams K.A., Liu W., Hu C.,
RA   Tong D., Haakenson J., Wang C., Zhang S., Pavlovicz R.E., Jones A.,
RA   Schmidt K.H., Tang J., Dong H., Shan B., Fang B., Radhakrishnan R.,
RA   Glazer P.M., Matthias P., Koomen J., Seto E., Bepler G., Nicosia S.V.,
RA   Chen J., Li C., Gu L., Li G.M., Bai W., Wang H., Zhang X.;
RT   "HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of
RT   MutSalpha.";
RL   Mol. Cell 55:31-46(2014).
RN   [32]
RP   INTERACTION WITH UBD.
RX   PubMed=25422469; DOI=10.1073/pnas.1403383111;
RA   Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L.,
RA   Chong S.S., Song J., Lee C.G.;
RT   "Disruption of FAT10-MAD2 binding inhibits tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014).
RN   [33]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH BANP AND KHDRBS1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=26080397; DOI=10.1073/pnas.1418603112;
RA   Nakka K.K., Chaudhary N., Joshi S., Bhat J., Singh K., Chatterjee S.,
RA   Malhotra R., De A., Santra M.K., Dilworth F.J., Chattopadhyay S.;
RT   "Nuclear matrix-associated protein SMAR1 regulates alternative splicing via
RT   HDAC6-mediated deacetylation of Sam68.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E3374-E3383(2015).
RN   [34]
RP   SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS OF HIS-216 AND HIS-611.
RX   PubMed=26246421; DOI=10.1038/srep12917;
RA   Ran J., Yang Y., Li D., Liu M., Zhou J.;
RT   "Deacetylation of alpha-tubulin and cortactin is required for HDAC6 to
RT   trigger ciliary disassembly.";
RL   Sci. Rep. 5:12917-12917(2015).
RN   [35]
RP   INTERACTION WITH DYNLL1.
RX   PubMed=31505170; DOI=10.1016/j.bbamcr.2019.118556;
RA   Olah J., Szunyogh S., Szenasi T., Szaniszlo T., Szabo A., Lehotzky A.,
RA   Berki T., Nyitray L., Ovadi J.;
RT   "Interactions between two regulatory proteins of microtubule dynamics,
RT   HDAC6, TPPP/p25, and the hub protein, DYNLL/LC8.";
RL   Biochim. Biophys. Acta 2019:118556-118556(2019).
RN   [36]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=30770470; DOI=10.1074/jbc.ra118.006374;
RA   Zhang M., Hu C., Moses N., Haakenson J., Xiang S., Quan D., Fang B.,
RA   Yang Z., Bai W., Bepler G., Li G.M., Zhang X.M.;
RT   "HDAC6 regulates DNA damage response via deacetylating MLH1.";
RL   J. Biol. Chem. 294:5813-5826(2019).
RN   [37]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=31857589; DOI=10.1038/s41467-019-13718-w;
RA   You Z., Jiang W.X., Qin L.Y., Gong Z., Wan W., Li J., Wang Y., Zhang H.,
RA   Peng C., Zhou T., Tang C., Liu W.;
RT   "Requirement for p62 acetylation in the aggregation of ubiquitylated
RT   proteins under nutrient stress.";
RL   Nat. Commun. 10:5792-5792(2019).
RN   [38]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH ATP13A2.
RX   PubMed=30538141; DOI=10.1083/jcb.201804165;
RA   Wang R., Tan J., Chen T., Han H., Tian R., Tan Y., Wu Y., Cui J., Chen F.,
RA   Li J., Lv L., Guan X., Shang S., Lu J., Zhang Z.;
RT   "ATP13A2 facilitates HDAC6 recruitment to lysosome to promote
RT   autophagosome-lysosome fusion.";
RL   J. Cell Biol. 218:267-284(2019).
RN   [39]
RP   FUNCTION, AND MUTAGENESIS OF HIS-216 AND HIS-611.
RX   PubMed=38534334; DOI=10.3390/cells13060490;
RA   Sun C., Xie K., Yang L., Cai S., Wang M., Zhu Y., Tao B., Zhu Y.;
RT   "HDAC6 Enhances Endoglin Expression through Deacetylation of Transcription
RT   Factor SP1, Potentiating BMP9-Induced Angiogenesis.";
RL   Cells 13:0-0(2024).
RN   [40]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=39567688; DOI=10.1038/s41586-024-08248-5;
RA   Jin J., Meng T., Yu Y., Wu S., Jiao C.C., Song S., Li Y.X., Zhang Y.,
RA   Zhao Y.Y., Li X., Wang Z., Liu Y.F., Huang R., Qin J., Chen Y., Cao H.,
RA   Tan X., Ge X., Jiang C., Xue J., Yuan J., Wu D., Wu W., Jiang C.Z.,
RA   Wang P.;
RT   "Human HDAC6 senses valine abundancy to regulate DNA damage.";
RL   Nature 0:0-0(2024).
RN   [41]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH G3BP1 AND SARS-COV-2 N
RP   PROTEIN, AND INDUCTION (MICROBIAL INFECTION).
RX   PubMed=39135075; DOI=10.1186/s12985-024-02460-5;
RA   Mukherjee A., Lo M., Chandra P., Datta Chaudhuri R., De P., Dutta S.,
RA   Chawla-Sarkar M.;
RT   "SARS-CoV-2 nucleocapsid protein promotes self-deacetylation by inducing
RT   HDAC6 to facilitate viral replication.";
RL   Virol. J. 21:186-186(2024).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 1109-1215 IN COMPLEX WITH ZINC
RP   IONS.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human HDAC6 zinc finger domain.";
RL   Submitted (FEB-2008) to the PDB data bank.
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 1109-1215 IN COMPLEX WITH ZINC
RP   IONS AND UBIQUITIN C-TERMINAL PEPTIDE RLRGG.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human HDAC6 zinc finger domain and ubiquitin C-
RT   terminal peptide RLRGG.";
RL   Submitted (APR-2009) to the PDB data bank.
CC   -!- FUNCTION: Deacetylates a wide range of non-histone substrates
CC       (PubMed:12024216, PubMed:18606987, PubMed:20308065, PubMed:24882211,
CC       PubMed:26246421, PubMed:30538141, PubMed:31857589, PubMed:30770470,
CC       PubMed:38534334, PubMed:39567688). Plays a central role in microtubule-
CC       dependent cell motility by mediating deacetylation of tubulin
CC       (PubMed:12024216, PubMed:20308065, PubMed:26246421). Required for cilia
CC       disassembly via deacetylation of alpha-tubulin (PubMed:17604723,
CC       PubMed:26246421). Alpha-tubulin deacetylation results in
CC       destabilization of dynamic microtubules (By similarity). Promotes
CC       deacetylation of CTTN, leading to actin polymerization, promotion of
CC       autophagosome-lysosome fusion and completion of autophagy
CC       (PubMed:30538141). Deacetylates SQSTM1 (PubMed:31857589). Deacetylates
CC       peroxiredoxins PRDX1 and PRDX2, decreasing their reducing activity
CC       (PubMed:18606987). Deacetylates antiviral protein RIGI in the presence
CC       of viral mRNAs which is required for viral RNA detection by RIGI (By
CC       similarity). Sequentially deacetylates and polyubiquitinates DNA
CC       mismatch repair protein MSH2 which leads to MSH2 degradation, reducing
CC       cellular sensitivity to DNA-damaging agents and decreasing cellular DNA
CC       mismatch repair activities (PubMed:24882211). Deacetylates DNA mismatch
CC       repair protein MLH1 which prevents recruitment of the MutL alpha
CC       complex (formed by the MLH1-PMS2 heterodimer) to the MutS alpha complex
CC       (formed by the MSH2-MSH6 heterodimer), leading to tolerance of DNA
CC       damage (PubMed:30770470). Deacetylates RHOT1/MIRO1 which blocks
CC       mitochondrial transport and mediates axon growth inhibition (By
CC       similarity). Deacetylates transcription factor SP1 which leads to
CC       increased expression of ENG, positively regulating angiogenesis
CC       (PubMed:38534334). Deacetylates KHDRBS1/SAM68 which regulates
CC       alternative splicing by inhibiting the inclusion of CD44 alternate
CC       exons (PubMed:26080397). Acts as a valine sensor by binding to valine
CC       through the primate-specific SE14 repeat region (PubMed:39567688). In
CC       valine deprivation conditions, translocates from the cytoplasm to the
CC       nucleus where it deacetylates TET2 which promotes TET2-dependent DNA
CC       demethylation, leading to DNA damage (PubMed:39567688). Promotes
CC       odontoblast differentiation following IPO7-mediated nuclear import and
CC       subsequent repression of RUNX2 expression (By similarity). In addition
CC       to its protein deacetylase activity, plays a key role in the
CC       degradation of misfolded proteins: when misfolded proteins are too
CC       abundant to be degraded by the chaperone refolding system and the
CC       ubiquitin-proteasome, mediates the transport of misfolded proteins to a
CC       cytoplasmic juxtanuclear structure called aggresome (PubMed:17846173).
CC       Probably acts as an adapter that recognizes polyubiquitinated misfolded
CC       proteins and targets them to the aggresome, facilitating their
CC       clearance by autophagy (PubMed:17846173). Involved in the MTA1-mediated
CC       epigenetic regulation of ESR1 expression in breast cancer
CC       (PubMed:24413532). {ECO:0000250|UniProtKB:D3ZVD8,
CC       ECO:0000250|UniProtKB:Q9Z2V5, ECO:0000269|PubMed:12024216,
CC       ECO:0000269|PubMed:17604723, ECO:0000269|PubMed:17846173,
CC       ECO:0000269|PubMed:18606987, ECO:0000269|PubMed:20308065,
CC       ECO:0000269|PubMed:24413532, ECO:0000269|PubMed:24882211,
CC       ECO:0000269|PubMed:26080397, ECO:0000269|PubMed:26246421,
CC       ECO:0000269|PubMed:30538141, ECO:0000269|PubMed:30770470,
CC       ECO:0000269|PubMed:31857589, ECO:0000269|PubMed:38534334,
CC       ECO:0000269|PubMed:39567688}.
CC   -!- FUNCTION: (Microbial infection) Deacetylates the SARS-CoV-2 N protein
CC       which promotes association of the viral N protein with human G3BP1,
CC       leading to disruption of cellular stress granule formation and
CC       facilitating viral replication. {ECO:0000269|PubMed:39135075}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-acetyl-L-lysyl-[protein] + H2O = L-lysyl-[protein] +
CC         acetate; Xref=Rhea:RHEA:58108, Rhea:RHEA-COMP:9752, Rhea:RHEA-
CC         COMP:10731, ChEBI:CHEBI:15377, ChEBI:CHEBI:29969, ChEBI:CHEBI:30089,
CC         ChEBI:CHEBI:61930; Evidence={ECO:0000269|PubMed:26080397,
CC         ECO:0000269|PubMed:30538141, ECO:0000269|PubMed:30770470,
CC         ECO:0000269|PubMed:31857589};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:58109;
CC         Evidence={ECO:0000269|PubMed:26080397, ECO:0000269|PubMed:30538141,
CC         ECO:0000269|PubMed:30770470, ECO:0000269|PubMed:31857589};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-acetyl-L-lysyl-[alpha-tubulin] + H2O = L-lysyl-[alpha-
CC         tubulin] + acetate; Xref=Rhea:RHEA:21548, Rhea:RHEA-COMP:11278,
CC         Rhea:RHEA-COMP:11279, ChEBI:CHEBI:15377, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:30089, ChEBI:CHEBI:61930;
CC         Evidence={ECO:0000269|PubMed:12024216, ECO:0000269|PubMed:20308065};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21549;
CC         Evidence={ECO:0000269|PubMed:12024216, ECO:0000269|PubMed:20308065};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000269|Ref.42,
CC         ECO:0000269|Ref.43};
CC       Note=Binds 3 Zn(2+) ions per subunit. {ECO:0000269|Ref.42,
CC       ECO:0000269|Ref.43};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:24882211}.
CC   -!- SUBUNIT: Forms a trimeric complex in the nucleus consisting of BANP,
CC       HDAC6 and KHDRBS1/SAM68; HDAC6 keeps KHDRBS1 in a deacetylated state
CC       which inhibits the inclusion of CD44 alternate exons (PubMed:26080397).
CC       The complex is disrupted by MAPK1/MAPK3-mediated phosphorylation of
CC       BANP which results in BANP export to the cytoplasm (PubMed:26080397).
CC       This facilitates acetylation of KHDRBS1 and CD44 variant exon inclusion
CC       (PubMed:26080397). Interacts with SIRT2 (via both phosphorylated,
CC       unphosphorylated, active or inactive forms); the interaction is
CC       necessary for the complex to interact with alpha-tubulin
CC       (PubMed:12620231, PubMed:17516032). Under proteasome impairment
CC       conditions, interacts with UBD via its histone deacetylase 1 and UBP-
CC       type zinc-finger regions (PubMed:19033385, PubMed:25422469). Interacts
CC       with BBIP1, CBFA2T3, CYLD, DDIT3/CHOP, ZMYND15, F-actin and HDAC11
CC       (PubMed:11533236, PubMed:11948178, PubMed:17872950, PubMed:19081074,
CC       PubMed:19893491). Interacts with RIPOR2; this interaction occurs during
CC       early myogenic differentiation and prevents HDAC6 to deacetylate
CC       tubulin (PubMed:24687993). Interacts with AURKA; AURKA-mediated
CC       phosphorylation of HDAC6 promotes deacetylation of alpha-tubulin
CC       (PubMed:17604723). Interacts with DYSF; this interaction occurs during
CC       early myogenic differentiation (PubMed:24687993). Interacts with TPPP;
CC       inhibiting the tubulin deacetylase activity of HDAC6 (PubMed:20308065,
CC       PubMed:23093407). Interacts with DYNLL1 (PubMed:31505170). Interacts
CC       with ATP13A2; the interaction results in recruitment of HDAC6 to
CC       lysosomes to promote CTTN deacetylation (PubMed:30538141). Interacts
CC       with CCDC141 (via the N-terminal region); inhibiting the deacetylase
CC       activity of HDAC6 (By similarity). Interacts with IPO7; the interaction
CC       facilitates HDAC6 nuclear translocation in dental papilla cells (By
CC       similarity). {ECO:0000250|UniProtKB:Q9Z2V5,
CC       ECO:0000269|PubMed:11533236, ECO:0000269|PubMed:11948178,
CC       ECO:0000269|PubMed:12620231, ECO:0000269|PubMed:17516032,
CC       ECO:0000269|PubMed:17604723, ECO:0000269|PubMed:17872950,
CC       ECO:0000269|PubMed:19033385, ECO:0000269|PubMed:19081074,
CC       ECO:0000269|PubMed:19893491, ECO:0000269|PubMed:20308065,
CC       ECO:0000269|PubMed:23093407, ECO:0000269|PubMed:24687993,
CC       ECO:0000269|PubMed:25422469, ECO:0000269|PubMed:26080397,
CC       ECO:0000269|PubMed:30538141, ECO:0000269|PubMed:31505170}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with G3BP1; the interaction
CC       increases during SARS-CoV-2 infection, promoting the association of
CC       G3BP1 with the viral N protein which disrupts stress granule formation
CC       and facilitates viral replication. {ECO:0000269|PubMed:39135075}.
CC   -!- INTERACTION:
CC       Q9UBN7; Q9NQ11: ATP13A2; NbExp=2; IntAct=EBI-301697, EBI-6308763;
CC       Q9UBN7; Q9HCU9: BRMS1; NbExp=2; IntAct=EBI-301697, EBI-714781;
CC       Q9UBN7; P35222: CTNNB1; NbExp=4; IntAct=EBI-301697, EBI-491549;
CC       Q9UBN7; Q14247: CTTN; NbExp=5; IntAct=EBI-301697, EBI-351886;
CC       Q9UBN7; Q9NQC7: CYLD; NbExp=4; IntAct=EBI-301697, EBI-2117940;
CC       Q9UBN7; Q14203-5: DCTN1; NbExp=6; IntAct=EBI-301697, EBI-25840379;
CC       Q9UBN7; P00533: EGFR; NbExp=12; IntAct=EBI-301697, EBI-297353;
CC       Q9UBN7; P42858: HTT; NbExp=9; IntAct=EBI-301697, EBI-466029;
CC       Q9UBN7; Q99836: MYD88; NbExp=6; IntAct=EBI-301697, EBI-447677;
CC       Q9UBN7; P17252: PRKCA; NbExp=2; IntAct=EBI-301697, EBI-1383528;
CC       Q9UBN7; O60260: PRKN; NbExp=6; IntAct=EBI-301697, EBI-716346;
CC       Q9UBN7; O43490: PROM1; NbExp=4; IntAct=EBI-301697, EBI-3447549;
CC       Q9UBN7; O43490-2: PROM1; NbExp=2; IntAct=EBI-301697, EBI-21452032;
CC       Q9UBN7; Q13148: TARDBP; NbExp=3; IntAct=EBI-301697, EBI-372899;
CC       Q9UBN7; Q62623: Cdc20; Xeno; NbExp=2; IntAct=EBI-301697, EBI-2256532;
CC       Q9UBN7; Q60598: Cttn; Xeno; NbExp=3; IntAct=EBI-301697, EBI-397955;
CC       Q9UBN7; P21146: GRK2; Xeno; NbExp=3; IntAct=EBI-301697, EBI-1036401;
CC       Q9UBN7; P04610: tat; Xeno; NbExp=10; IntAct=EBI-301697, EBI-7845069;
CC       Q9UBN7; P03409: Tax; Xeno; NbExp=4; IntAct=EBI-301697, EBI-5236464;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12024216,
CC       ECO:0000269|PubMed:24687993, ECO:0000269|PubMed:26246421,
CC       ECO:0000269|PubMed:30770470, ECO:0000269|PubMed:39567688}. Cytoplasm,
CC       cytoskeleton {ECO:0000269|PubMed:12024216}. Nucleus
CC       {ECO:0000269|PubMed:24882211, ECO:0000269|PubMed:26080397,
CC       ECO:0000269|PubMed:30770470, ECO:0000269|PubMed:39567688}. Perikaryon
CC       {ECO:0000250|UniProtKB:Q9Z2V5}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:Q9Z2V5}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q9Z2V5}. Cell projection, cilium
CC       {ECO:0000269|PubMed:17604723}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:26246421}. Cytoplasm,
CC       cytoskeleton, cilium basal body {ECO:0000269|PubMed:26246421}.
CC       Note=Mainly cytoplasmic where it is associated with microtubules
CC       (PubMed:12024216). Can shuttle between the cytoplasm and the nucleus
CC       (PubMed:39567688). Retained in the cytoplasm by binding to valine via
CC       the primate-specific SE14 repeat region while valine deprivation
CC       induces nuclear localization (PubMed:39567688). Found exclusively in
CC       the cytoplasm in proliferative cells with a fraction found in the
CC       nucleus during differentiation (By similarity). May translocate to the
CC       nucleus following DNA damage (PubMed:30770470).
CC       {ECO:0000250|UniProtKB:Q9Z2V5, ECO:0000269|PubMed:12024216,
CC       ECO:0000269|PubMed:30770470, ECO:0000269|PubMed:39567688}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=HDAC6p131;
CC         IsoId=Q9UBN7-1; Sequence=Displayed;
CC       Name=2; Synonyms=HDAC6p114;
CC         IsoId=Q9UBN7-2; Sequence=VSP_044576;
CC   -!- INDUCTION: (Microbial infection) Up-regulated by the presence of SARS-
CC       CoV-2 N protein during viral infection (PubMed:39135075). The SARS-CoV-
CC       2 N protein enhances HDAC6 stability during infection by reducing its
CC       proteasomal degradation, leading to elevated HDAC6 levels
CC       (PubMed:39135075). {ECO:0000269|PubMed:39135075}.
CC   -!- DOMAIN: Histone deacetylase domain 1 mediates the E3 ubiquitin-protein
CC       ligase activity. {ECO:0000269|PubMed:30770470}.
CC   -!- DOMAIN: The primate-specific SE14 repeat region contains seven SE14
CC       repeats with the consensus sequence X-L-X-Q-T-X-S-E-X-A-X-G-G-A and
CC       mediates binding to valine. {ECO:0000269|PubMed:39567688}.
CC   -!- PTM: Phosphorylated by AURKA; phosphorylation increases HDAC6-mediated
CC       deacetylation of alpha-tubulin and subsequent disassembly of cilia.
CC       {ECO:0000269|PubMed:17604723}.
CC   -!- PTM: Ubiquitinated. Its polyubiquitination however does not lead to its
CC       degradation. {ECO:0000269|PubMed:12354939}.
CC   -!- PTM: Sumoylated in vitro. {ECO:0000269|PubMed:12032081}.
CC   -!- DISEASE: Chondrodysplasia with platyspondyly, distinctive
CC       brachydactyly, hydrocephaly, and microphthalmia (CDP-PBHM)
CC       [MIM:300863]: A disease characterized by chondrodysplasia, severe
CC       platyspondyly, hydrocephaly, and facial features with microphthalmia.
CC       Bone abnormalities include a distinctive metaphyseal cupping of the
CC       metacarpals, metatarsals, and phalanges. Affected females show a milder
CC       phenotype with small stature, sometimes associated with body asymmetry
CC       and mild intellectual disability. {ECO:0000269|PubMed:20181727}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Required for TGF-beta1-activated gene
CC       expression associated with epithelial-mesenchymal transition (EMT) in
CC       A549 cells. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the histone deacetylase family. HD type 2
CC       subfamily. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to be a histone deacetylase
CC       (PubMed:10220385). However, subsequent work has shown that it is
CC       predominantly cytoplasmic and deacetylates a range of non-histone
CC       substrates (PubMed:12024216, PubMed:18606987, PubMed:20308065,
CC       PubMed:24882211, PubMed:26246421, PubMed:30538141, PubMed:31857589,
CC       PubMed:38534334, PubMed:39567688). {ECO:0000269|PubMed:10220385,
CC       ECO:0000269|PubMed:12024216, ECO:0000269|PubMed:18606987,
CC       ECO:0000269|PubMed:20308065, ECO:0000269|PubMed:24882211,
CC       ECO:0000269|PubMed:26246421, ECO:0000269|PubMed:30538141,
CC       ECO:0000269|PubMed:31857589, ECO:0000269|PubMed:38534334,
CC       ECO:0000269|PubMed:39567688}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA74924.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF132609; AAD29048.1; -; mRNA.
DR   EMBL; AB020708; BAA74924.2; ALT_INIT; mRNA.
DR   EMBL; AJ011972; CAA09893.1; -; mRNA.
DR   EMBL; AF196971; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471224; EAW50748.1; -; Genomic_DNA.
DR   EMBL; BC013737; AAH13737.1; -; mRNA.
DR   EMBL; BC069243; AAH69243.1; -; mRNA.
DR   CCDS; CCDS14306.1; -. [Q9UBN7-1]
DR   RefSeq; NP_001308155.1; NM_001321226.2. [Q9UBN7-1]
DR   RefSeq; NP_001308156.1; NM_001321227.2. [Q9UBN7-1]
DR   RefSeq; NP_001308157.1; NM_001321228.2. [Q9UBN7-1]
DR   RefSeq; NP_001308158.1; NM_001321229.1. [Q9UBN7-1]
DR   RefSeq; NP_006035.2; NM_006044.3. [Q9UBN7-1]
DR   PDB; 3C5K; X-ray; 1.55 A; A=1109-1215.
DR   PDB; 3GV4; X-ray; 1.72 A; A=1109-1215.
DR   PDB; 3PHD; X-ray; 3.00 A; A/B/C/D=1109-1215.
DR   PDB; 5B8D; X-ray; 1.05 A; A=1109-1213.
DR   PDB; 5EDU; X-ray; 2.79 A; A/B=479-835.
DR   PDB; 5KH3; X-ray; 1.60 A; A=1109-1213.
DR   PDB; 5KH7; X-ray; 1.70 A; A=1109-1213.
DR   PDB; 5KH9; X-ray; 1.07 A; A=1109-1213.
DR   PDB; 5WBN; X-ray; 1.64 A; A=1108-1213.
DR   PDB; 5WPB; X-ray; 1.55 A; A=1109-1208.
DR   PDB; 6CE6; X-ray; 1.60 A; A=1109-1213.
DR   PDB; 6CE8; X-ray; 1.55 A; A=1109-1213.
DR   PDB; 6CEA; X-ray; 1.60 A; A=1109-1213.
DR   PDB; 6CEC; X-ray; 1.55 A; A=1109-1213.
DR   PDB; 6CED; X-ray; 1.70 A; A=1109-1213.
DR   PDB; 6CEE; X-ray; 1.55 A; A=1109-1213.
DR   PDB; 6CEF; X-ray; 1.80 A; A=1109-1213.
DR   PDB; 7ZYU; X-ray; 2.43 A; A=1108-1215.
DR   PDB; 8G43; X-ray; 1.55 A; A=1109-1213.
DR   PDB; 8G44; X-ray; 1.55 A; A=1109-1213.
DR   PDB; 8G45; X-ray; 1.62 A; A=1109-1213.
DR   PDBsum; 3C5K; -.
DR   PDBsum; 3GV4; -.
DR   PDBsum; 3PHD; -.
DR   PDBsum; 5B8D; -.
DR   PDBsum; 5EDU; -.
DR   PDBsum; 5KH3; -.
DR   PDBsum; 5KH7; -.
DR   PDBsum; 5KH9; -.
DR   PDBsum; 5WBN; -.
DR   PDBsum; 5WPB; -.
DR   PDBsum; 6CE6; -.
DR   PDBsum; 6CE8; -.
DR   PDBsum; 6CEA; -.
DR   PDBsum; 6CEC; -.
DR   PDBsum; 6CED; -.
DR   PDBsum; 6CEE; -.
DR   PDBsum; 6CEF; -.
DR   PDBsum; 7ZYU; -.
DR   PDBsum; 8G43; -.
DR   PDBsum; 8G44; -.
DR   PDBsum; 8G45; -.
DR   AlphaFoldDB; Q9UBN7; -.
DR   SASBDB; Q9UBN7; -.
DR   SMR; Q9UBN7; -.
DR   BioGRID; 115330; 933.
DR   CORUM; Q9UBN7; -.
DR   DIP; DIP-27544N; -.
DR   FunCoup; Q9UBN7; 1247.
DR   IntAct; Q9UBN7; 175.
DR   MINT; Q9UBN7; -.
DR   STRING; 9606.ENSP00000365804; -.
DR   BindingDB; Q9UBN7; -.
DR   ChEMBL; CHEMBL1865; -.
DR   DrugBank; DB07553; 9,9,9-TRIFLUORO-8-OXO-N-PHENYLNONANAMIDE.
DR   DrugBank; DB12565; Abexinostat.
DR   DrugBank; DB05015; Belinostat.
DR   DrugBank; DB13346; Bufexamac.
DR   DrugBank; DB15449; Citarinostat.
DR   DrugBank; DB01262; Decitabine.
DR   DrugBank; DB11841; Entinostat.
DR   DrugBank; DB12645; Givinostat.
DR   DrugBank; DB14979; Martinostat.
DR   DrugBank; DB06603; Panobinostat.
DR   DrugBank; DB06819; Phenylbutyric acid.
DR   DrugBank; DB05223; Pracinostat.
DR   DrugBank; DB03766; Propanoic acid.
DR   DrugBank; DB12847; Pyroxamide.
DR   DrugBank; DB06176; Romidepsin.
DR   DrugBank; DB00313; Valproic acid.
DR   DrugBank; DB02546; Vorinostat.
DR   DrugCentral; Q9UBN7; -.
DR   GuidetoPHARMACOLOGY; 2618; -.
DR   GlyGen; Q9UBN7; 4 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; Q9UBN7; -.
DR   PhosphoSitePlus; Q9UBN7; -.
DR   BioMuta; HDAC6; -.
DR   DMDM; 205371758; -.
DR   jPOST; Q9UBN7; -.
DR   MassIVE; Q9UBN7; -.
DR   PaxDb; 9606-ENSP00000334061; -.
DR   PeptideAtlas; Q9UBN7; -.
DR   ProteomicsDB; 84019; -. [Q9UBN7-1]
DR   Pumba; Q9UBN7; -.
DR   Antibodypedia; 3788; 1154 antibodies from 47 providers.
DR   DNASU; 10013; -.
DR   Ensembl; ENST00000334136.11; ENSP00000334061.5; ENSG00000094631.22. [Q9UBN7-1]
DR   Ensembl; ENST00000376610.7; ENSP00000365795.3; ENSG00000094631.22. [Q9UBN7-1]
DR   Ensembl; ENST00000376619.7; ENSP00000365804.2; ENSG00000094631.22. [Q9UBN7-1]
DR   Ensembl; ENST00000376643.7; ENSP00000365831.3; ENSG00000094631.22. [Q9UBN7-1]
DR   Ensembl; ENST00000423941.6; ENSP00000392815.2; ENSG00000094631.22. [Q9UBN7-1]
DR   Ensembl; ENST00000440653.2; ENSP00000394377.2; ENSG00000094631.22. [Q9UBN7-1]
DR   Ensembl; ENST00000443563.6; ENSP00000402751.2; ENSG00000094631.22. [Q9UBN7-1]
DR   Ensembl; ENST00000643374.2; ENSP00000496046.1; ENSG00000094631.22. [Q9UBN7-1]
DR   Ensembl; ENST00000644068.1; ENSP00000496013.1; ENSG00000094631.22. [Q9UBN7-1]
DR   GeneID; 10013; -.
DR   KEGG; hsa:10013; -.
DR   MANE-Select; ENST00000334136.11; ENSP00000334061.5; NM_006044.4; NP_006035.2.
DR   UCSC; uc004dks.2; human. [Q9UBN7-1]
DR   AGR; HGNC:14064; -.
DR   CTD; 10013; -.
DR   DisGeNET; 10013; -.
DR   GeneCards; HDAC6; -.
DR   HGNC; HGNC:14064; HDAC6.
DR   HPA; ENSG00000094631; Low tissue specificity.
DR   MalaCards; HDAC6; -.
DR   MIM; 300272; gene.
DR   MIM; 300863; phenotype.
DR   OpenTargets; ENSG00000094631; -.
DR   Orphanet; 163966; X-linked dominant chondrodysplasia, Chassaing-Lacombe type.
DR   VEuPathDB; HostDB:ENSG00000094631; -.
DR   eggNOG; KOG1343; Eukaryota.
DR   GeneTree; ENSGT00940000159563; -.
DR   HOGENOM; CLU_007727_2_1_1; -.
DR   InParanoid; Q9UBN7; -.
DR   OMA; HTRSHVN; -.
DR   OrthoDB; 424012at2759; -.
DR   PAN-GO; Q9UBN7; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9UBN7; -.
DR   BioCyc; MetaCyc:HS01799-MONOMER; -.
DR   BRENDA; 3.5.1.98; 2681.
DR   PathwayCommons; Q9UBN7; -.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3371511; HSF1 activation.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-5617833; Cilium Assembly.
DR   Reactome; R-HSA-8878166; Transcriptional regulation by RUNX2.
DR   Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation.
DR   Reactome; R-HSA-9613829; Chaperone Mediated Autophagy.
DR   Reactome; R-HSA-9615710; Late endosomal microautophagy.
DR   Reactome; R-HSA-9646399; Aggrephagy.
DR   SABIO-RK; Q9UBN7; -.
DR   SignaLink; Q9UBN7; -.
DR   SIGNOR; Q9UBN7; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 10013; 18 hits in 818 CRISPR screens.
DR   CD-CODE; 4CAAAA97; Synthetic Condensate 000349.
DR   CD-CODE; 9B5E283A; Synthetic Condensate 000373.
DR   CD-CODE; DEE660B4; Stress granule.
DR   ChiTaRS; HDAC6; human.
DR   EvolutionaryTrace; Q9UBN7; -.
DR   GeneWiki; HDAC6; -.
DR   GenomeRNAi; 10013; -.
DR   Pharos; Q9UBN7; Tclin.
DR   PRO; PR:Q9UBN7; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9UBN7; protein.
DR   Bgee; ENSG00000094631; Expressed in right hemisphere of cerebellum and 204 other cell types or tissues.
DR   ExpressionAtlas; Q9UBN7; baseline and differential.
DR   GO; GO:0016235; C:aggresome; IDA:BHF-UCL.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:1904115; C:axon cytoplasm; IEA:GOC.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0031252; C:cell leading edge; IDA:BHF-UCL.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0000118; C:histone deacetylase complex; IDA:UniProtKB.
DR   GO; GO:0016234; C:inclusion body; IDA:BHF-UCL.
DR   GO; GO:0005874; C:microtubule; IDA:UniProtKB.
DR   GO; GO:0005875; C:microtubule associated complex; IDA:BHF-UCL.
DR   GO; GO:0005771; C:multivesicular body; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW.
DR   GO; GO:0043014; F:alpha-tubulin binding; IDA:BHF-UCL.
DR   GO; GO:0042030; F:ATPase inhibitor activity; IMP:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0048487; F:beta-tubulin binding; IEA:Ensembl.
DR   GO; GO:0070840; F:dynein complex binding; IDA:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0004407; F:histone deacetylase activity; IDA:MGI.
DR   GO; GO:0141221; F:histone deacetylase activity, hydrolytic mechanism; IEA:UniProtKB-EC.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0051879; F:Hsp90 protein binding; IDA:BHF-UCL.
DR   GO; GO:0008017; F:microtubule binding; IDA:BHF-UCL.
DR   GO; GO:0051787; F:misfolded protein binding; EXP:Reactome.
DR   GO; GO:0036479; F:peroxidase inhibitor activity; IMP:BHF-UCL.
DR   GO; GO:0031593; F:polyubiquitin modification-dependent protein binding; IDA:BHF-UCL.
DR   GO; GO:0033558; F:protein lysine deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; IDA:BHF-UCL.
DR   GO; GO:0001222; F:transcription corepressor binding; IPI:ARUK-UCL.
DR   GO; GO:0042903; F:tubulin deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IEA:Ensembl.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0007015; P:actin filament organization; IEA:Ensembl.
DR   GO; GO:0070842; P:aggresome assembly; IMP:BHF-UCL.
DR   GO; GO:0140374; P:antiviral innate immune response; IEA:Ensembl.
DR   GO; GO:0019896; P:axonal transport of mitochondrion; IGI:ARUK-UCL.
DR   GO; GO:0034605; P:cellular response to heat; TAS:Reactome.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IMP:BHF-UCL.
DR   GO; GO:0071218; P:cellular response to misfolded protein; IEA:Ensembl.
DR   GO; GO:0071374; P:cellular response to parathyroid hormone stimulus; IEA:Ensembl.
DR   GO; GO:0035967; P:cellular response to topologically incorrect protein; IMP:BHF-UCL.
DR   GO; GO:0060271; P:cilium assembly; TAS:Reactome.
DR   GO; GO:0061523; P:cilium disassembly; IDA:UniProtKB.
DR   GO; GO:0048668; P:collateral sprouting; IEA:Ensembl.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0040029; P:epigenetic regulation of gene expression; IBA:GO_Central.
DR   GO; GO:0043131; P:erythrocyte enucleation; IEA:Ensembl.
DR   GO; GO:0006886; P:intracellular protein transport; IMP:BHF-UCL.
DR   GO; GO:0032418; P:lysosome localization; IMP:BHF-UCL.
DR   GO; GO:1905336; P:negative regulation of aggrephagy; IDA:UniProt.
DR   GO; GO:0048843; P:negative regulation of axon extension involved in axon guidance; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; IMP:UniProtKB.
DR   GO; GO:0010727; P:negative regulation of hydrogen peroxide metabolic process; IMP:BHF-UCL.
DR   GO; GO:0007026; P:negative regulation of microtubule depolymerization; IEA:Ensembl.
DR   GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IMP:ARUK-UCL.
DR   GO; GO:0043242; P:negative regulation of protein-containing complex disassembly; IMP:BHF-UCL.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IMP:BHF-UCL.
DR   GO; GO:0070845; P:polyubiquitinated misfolded protein transport; IMP:BHF-UCL.
DR   GO; GO:1900409; P:positive regulation of cellular response to oxidative stress; IEA:Ensembl.
DR   GO; GO:1904056; P:positive regulation of cholangiocyte proliferation; IEA:Ensembl.
DR   GO; GO:0050775; P:positive regulation of dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; IMP:ARUK-UCL.
DR   GO; GO:1900246; P:positive regulation of RIG-I signaling pathway; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:1905091; P:positive regulation of type 2 mitophagy; IEA:Ensembl.
DR   GO; GO:0006476; P:protein deacetylation; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Ensembl.
DR   GO; GO:0006515; P:protein quality control for misfolded or incompletely synthesized proteins; IMP:BHF-UCL.
DR   GO; GO:0032984; P:protein-containing complex disassembly; IEA:Ensembl.
DR   GO; GO:0060765; P:regulation of androgen receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1903146; P:regulation of autophagy of mitochondrion; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0070201; P:regulation of establishment of protein localization; IEA:Ensembl.
DR   GO; GO:0045598; P:regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0016241; P:regulation of macroautophagy; IMP:BHF-UCL.
DR   GO; GO:0060632; P:regulation of microtubule-based movement; IC:BHF-UCL.
DR   GO; GO:0010821; P:regulation of mitochondrion organization; IEA:Ensembl.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl.
DR   GO; GO:0035902; P:response to immobilization stress; IEA:Ensembl.
DR   GO; GO:0051788; P:response to misfolded protein; IMP:BHF-UCL.
DR   GO; GO:0090042; P:tubulin deacetylation; IDA:UniProtKB.
DR   GO; GO:0061734; P:type 2 mitophagy; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0043162; P:ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway; IEA:Ensembl.
DR   CDD; cd11682; HDAC6-dom1; 1.
DR   CDD; cd10003; HDAC6-dom2; 1.
DR   FunFam; 3.30.40.10:FF:000342; Histone deacetylase 6; 1.
DR   FunFam; 3.40.800.20:FF:000005; histone deacetylase 6; 2.
DR   Gene3D; 3.40.800.20; Histone deacetylase domain; 2.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR050284; HDAC_PDAC.
DR   InterPro; IPR000286; His_deacetylse.
DR   InterPro; IPR023801; His_deacetylse_dom.
DR   InterPro; IPR037138; His_deacetylse_dom_sf.
DR   InterPro; IPR023696; Ureohydrolase_dom_sf.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR001607; Znf_UBP.
DR   PANTHER; PTHR10625:SF21; HISTONE DEACETYLASE 6; 1.
DR   PANTHER; PTHR10625; HISTONE DEACETYLASE HDAC1-RELATED; 1.
DR   Pfam; PF00850; Hist_deacetyl; 2.
DR   Pfam; PF02148; zf-UBP; 1.
DR   PRINTS; PR01270; HDASUPER.
DR   SMART; SM00290; ZnF_UBP; 1.
DR   SUPFAM; SSF52768; Arginase/deacetylase; 2.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   PROSITE; PS50271; ZF_UBP; 1.
DR   neXtProt; NX_Q9UBN7; -.
DR   PharmGKB; PA29231; -.
DR   TreeFam; TF106173; -.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Alternative splicing; Autophagy;
KW   Cell projection; Chromatin regulator; Cytoplasm; Cytoskeleton; Hydrolase;
KW   Metal-binding; Methylation; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..1215
FT                   /note="Protein deacetylase HDAC6"
FT                   /id="PRO_0000114703"
FT   REPEAT          919..932
FT                   /note="SE14-1"
FT                   /evidence="ECO:0000269|PubMed:39567688"
FT   REPEAT          933..946
FT                   /note="SE14-2"
FT                   /evidence="ECO:0000269|PubMed:39567688"
FT   REPEAT          947..960
FT                   /note="SE14-3"
FT                   /evidence="ECO:0000269|PubMed:39567688"
FT   REPEAT          961..974
FT                   /note="SE14-4"
FT                   /evidence="ECO:0000269|PubMed:39567688"
FT   REPEAT          975..988
FT                   /note="SE14-5"
FT                   /evidence="ECO:0000269|PubMed:39567688"
FT   REPEAT          989..1002
FT                   /note="SE14-6"
FT                   /evidence="ECO:0000269|PubMed:39567688"
FT   REPEAT          1003..1016
FT                   /note="SE14-7"
FT                   /evidence="ECO:0000269|PubMed:39567688"
FT   ZN_FING         1111..1209
FT                   /note="UBP-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   REGION          1..44
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          87..404
FT                   /note="Histone deacetylase 1"
FT   REGION          445..464
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          482..800
FT                   /note="Histone deacetylase 2"
FT   REGION          842..863
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          994..1047
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1154..1156
FT                   /note="Ubiquitin binding"
FT                   /evidence="ECO:0000269|Ref.43"
FT   REGION          1182..1189
FT                   /note="Ubiquitin binding"
FT                   /evidence="ECO:0000269|Ref.43"
FT   MOTIF           67..76
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2V5"
FT   COMPBIAS        1..11
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        18..28
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        449..463
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1018..1047
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        216
FT                   /note="1"
FT                   /evidence="ECO:0000269|PubMed:12354939"
FT   ACT_SITE        611
FT                   /note="2"
FT                   /evidence="ECO:0000269|PubMed:12354939"
FT   BINDING         1113
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1115
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1133
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1136
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1145
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1148
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1153
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1160
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1164
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1170
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1183
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   BINDING         1186
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502,
FT                   ECO:0000269|Ref.42, ECO:0000269|Ref.43"
FT   MOD_RES         22
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         33
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2V5"
FT   MOD_RES         1016
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1021
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1027
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1031
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1034
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1035
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1040
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         1..152
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_044576"
FT   VARIANT         994
FT                   /note="T -> I (in dbSNP:rs1127346)"
FT                   /evidence="ECO:0000269|PubMed:10220385, ECO:0000269|Ref.4"
FT                   /id="VAR_046300"
FT   VARIANT         1200
FT                   /note="N -> D (in dbSNP:rs151130423)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_068962"
FT   MUTAGEN         216
FT                   /note="H->A: Reduces histone deacetylase activity. Does not
FT                   affect HDAC6-mediated deacetylation of alpha-tubulin.
FT                   Abolishes HDAC6-mediated deacetylation of alpha-tubulin;
FT                   when associated with A-611."
FT                   /evidence="ECO:0000269|PubMed:12354939,
FT                   ECO:0000269|PubMed:26246421, ECO:0000269|PubMed:38534334"
FT   MUTAGEN         611
FT                   /note="H->A: Reduces histone deacetylase activity.
FT                   Abolishes HDAC6-mediated deacetylation of alpha-tubulin.
FT                   Abolishes HDAC6-mediated deacetylation of alpha-tubulin;
FT                   when associated with A-216."
FT                   /evidence="ECO:0000269|PubMed:12354939,
FT                   ECO:0000269|PubMed:26246421, ECO:0000269|PubMed:38534334"
FT   STRAND          481..484
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           487..490
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           505..516
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   TURN            517..522
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          523..526
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           533..536
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   TURN            537..539
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           542..550
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           551..553
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           556..563
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          566..568
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           575..593
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   TURN            594..596
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          599..603
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          621..623
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           625..637
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          643..647
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          649..651
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           654..659
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   TURN            660..662
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          666..673
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   TURN            675..678
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           694..696
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          699..705
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           712..721
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           723..730
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          733..739
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          742..744
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   TURN            748..750
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           756..766
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           770..772
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          774..778
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           784..798
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   HELIX           814..827
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   TURN            828..830
FT                   /evidence="ECO:0007829|PDB:5EDU"
FT   STRAND          1108..1111
FT                   /evidence="ECO:0007829|PDB:7ZYU"
FT   HELIX           1116..1118
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   TURN            1134..1136
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   STRAND          1140..1145
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   TURN            1146..1148
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   STRAND          1151..1153
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   TURN            1155..1158
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   HELIX           1160..1168
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   STRAND          1172..1175
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   TURN            1176..1178
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   STRAND          1181..1183
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   TURN            1184..1187
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   STRAND          1188..1190
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   HELIX           1193..1195
FT                   /evidence="ECO:0007829|PDB:5B8D"
FT   HELIX           1196..1206
FT                   /evidence="ECO:0007829|PDB:5B8D"
SQ   SEQUENCE   1215 AA;  131419 MW;  6F17731268A33114 CRC64;
     MTSTGQDSTT TRQRRSRQNP QSPPQDSSVT SKRNIKKGAV PRSIPNLAEV KKKGKMKKLG
     QAMEEDLIVG LQGMDLNLEA EALAGTGLVL DEQLNEFHCL WDDSFPEGPE RLHAIKEQLI
     QEGLLDRCVS FQARFAEKEE LMLVHSLEYI DLMETTQYMN EGELRVLADT YDSVYLHPNS
     YSCACLASGS VLRLVDAVLG AEIRNGMAII RPPGHHAQHS LMDGYCMFNH VAVAARYAQQ
     KHRIRRVLIV DWDVHHGQGT QFTFDQDPSV LYFSIHRYEQ GRFWPHLKAS NWSTTGFGQG
     QGYTINVPWN QVGMRDADYI AAFLHVLLPV ALEFQPQLVL VAAGFDALQG DPKGEMAATP
     AGFAQLTHLL MGLAGGKLIL SLEGGYNLRA LAEGVSASLH TLLGDPCPML ESPGAPCRSA
     QASVSCALEA LEPFWEVLVR STETVERDNM EEDNVEESEE EGPWEPPVLP ILTWPVLQSR
     TGLVYDQNMM NHCNLWDSHH PEVPQRILRI MCRLEELGLA GRCLTLTPRP ATEAELLTCH
     SAEYVGHLRA TEKMKTRELH RESSNFDSIY ICPSTFACAQ LATGAACRLV EAVLSGEVLN
     GAAVVRPPGH HAEQDAACGF CFFNSVAVAA RHAQTISGHA LRILIVDWDV HHGNGTQHMF
     EDDPSVLYVS LHRYDHGTFF PMGDEGASSQ IGRAAGTGFT VNVAWNGPRM GDADYLAAWH
     RLVLPIAYEF NPELVLVSAG FDAARGDPLG GCQVSPEGYA HLTHLLMGLA SGRIILILEG
     GYNLTSISES MAACTRSLLG DPPPLLTLPR PPLSGALASI TETIQVHRRY WRSLRVMKVE
     DREGPSSSKL VTKKAPQPAK PRLAERMTTR EKKVLEAGMG KVTSASFGEE STPGQTNSET
     AVVALTQDQP SEAATGGATL AQTISEAAIG GAMLGQTTSE EAVGGATPDQ TTSEETVGGA
     ILDQTTSEDA VGGATLGQTT SEEAVGGATL AQTTSEAAME GATLDQTTSE EAPGGTELIQ
     TPLASSTDHQ TPPTSPVQGT TPQISPSTLI GSLRTLELGS ESQGASESQA PGEENLLGEA
     AGGQDMADSM LMQGSRGLTD QAIFYAVTPL PWCPHLVAVC PIPAAGLDVT QPCGDCGTIQ
     ENWVCLSCYQ VYCGRYINGH MLQHHGNSGH PLVLSYIDLS AWCYYCQAYV HHQALLDVKN
     IAHQNKFGED MPHPH
//
